-
Mashup Score: 0Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial - 2 year(s) ago
The addition of galunisertib to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer improved the complete response rate to 32%, was well tolerated, and warrants further assessment in randomised trials.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial - 2 year(s) ago
The addition of galunisertib to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer improved the complete response rate to 32%, was well tolerated, and warrants further assessment in randomised trials.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Also in the Sept issue: #Galunisertib plus #neoadjuvant #chemoradiotherapy in patients with locally advanced #rectalcancer: a single-arm, phase 2 trial https://t.co/2qwxzYXaqj